Skip to Content
Full Title A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer
Protocol Number NLG0405
Principal Investigator(s) Clifford S Cho, MD, FACS
Division General Surgery
Status Active, not recruiting

The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.

Other Clinical Trials in the Department of Surgery Copyright © 2015 The Board of Regents of the University of Wisconsin System